[BeyondPost | Reporter Kim Shin]
REV-MED (CEO Edward BG Shin) participated in Arab Health 2025, held from January 27 to 30 in Dubai, UAE, where it unveiled its proprietary technology for biological substance separation and concentration, signaling an ambitious push for global market expansion. The company has already obtained technical certifications from Japanese (PMDA) and Chinese (NMPA) regulatory authorities and is now reinforcing its presence in the Middle East and beyond.
In the Middle East, REV-MED has successfully introduced its TriCell system, which enables the separation and concentration of biological materials. It has established cooperative networks with local medical institutions and possesses the technology to efficiently isolate specific blood cell layers such as T-cells, lymphocytes, and mononuclear cells. These capabilities are also being utilized for expansion into the anti-aging and aesthetic markets.
At the exhibition, the company also presented its Rewave device, which uses microwave technology for skin regeneration and lifting, and its full lineup of Brifill HA fillers, drawing significant interest from aesthetic medicine professionals. Certification by Japan’s PMDA and China’s NMPA was prominently highlighted at the booth.
The head of the Global Business Division stated,
“The global biopharmaceutical market is projected to reach KRW 500 trillion by 2027. REV-MED’s unique cell processing technology will offer a new paradigm in anti-aging and treatment of intractable diseases, challenging the dominance of conventional pharmaceuticals.”
The company also announced its intention to strengthen academic credibility with a goal of publishing over five international journal articles per year to solidify its scientific influence in the global bio-medical field.
Source: BeyondPost
Original article: https://www.beyondpost.co.kr
[BeyondPost | Reporter Kim Shin]
REV-MED (CEO Edward BG Shin) participated in Arab Health 2025, held from January 27 to 30 in Dubai, UAE, where it unveiled its proprietary technology for biological substance separation and concentration, signaling an ambitious push for global market expansion. The company has already obtained technical certifications from Japanese (PMDA) and Chinese (NMPA) regulatory authorities and is now reinforcing its presence in the Middle East and beyond.
In the Middle East, REV-MED has successfully introduced its TriCell system, which enables the separation and concentration of biological materials. It has established cooperative networks with local medical institutions and possesses the technology to efficiently isolate specific blood cell layers such as T-cells, lymphocytes, and mononuclear cells. These capabilities are also being utilized for expansion into the anti-aging and aesthetic markets.
At the exhibition, the company also presented its Rewave device, which uses microwave technology for skin regeneration and lifting, and its full lineup of Brifill HA fillers, drawing significant interest from aesthetic medicine professionals. Certification by Japan’s PMDA and China’s NMPA was prominently highlighted at the booth.
The head of the Global Business Division stated,
The company also announced its intention to strengthen academic credibility with a goal of publishing over five international journal articles per year to solidify its scientific influence in the global bio-medical field.
Source: BeyondPost
Original article: https://www.beyondpost.co.kr